Teva Statement Following New York Jury Ruling in Opioids Trial
31 December 2021 - 5:29AM
Business Wire
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical
Industries, Ltd. (NYSE and TASE: TEVA) strongly disagrees with
today’s outcome and will prepare for a swift appeal as well as
continue to pursue a mistrial.
In NY, the plaintiffs presented no evidence of medically
unnecessary prescriptions, suspicious or diverted orders, no
evidence of oversupply by the defendants – or any indication of
what volumes were appropriate – and no causal relationship between
Teva’s conduct including its marketing and any harm to the public
in the state.
Prior to deliberation, Teva sought a mistrial based on, among
other issues, the state’s misrepresentation of the amount of
opioids sold by Teva in NY by more than 500 times.
Teva continues to focus on increasing access to essential
medicines to patients, including opioid medications for approved
indications. Most importantly, the Company continues to pursue a
national settlement in the best interest of patients.
As recently as last month, a court in California issued a
decision finding that Teva did not cause a public nuisance in
Orange County, Los Angeles County, Santa Clara County and the City
of Oakland and that Teva did not make any false or misleading
statements in connection with marketing prescription opioids in
California.
Additionally, last month the Oklahoma Supreme Court overturned
an earlier judgment against a pharmaceutical manufacturer and ruled
that the public nuisance law in Oklahoma does not extend to the
manufacturing, marketing and selling of prescription opioids.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211230005283/en/
IR Contacts
United States Ran Meir (267) 468-4475
Israel Yael Ashman 972 (3) 914-8262
PR Contacts
United States Kelley Dougherty (973) 658-0237
Yonatan Beker (973) 264 7378
Teva Pharmaceutical Indu... (NYSE:TEVA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Teva Pharmaceutical Indu... (NYSE:TEVA)
Historical Stock Chart
From Apr 2023 to Apr 2024